MML Investors Services LLC Purchases 18,840 Shares of Boston Scientific Co. (NYSE:BSX)

MML Investors Services LLC increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 21.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 107,648 shares of the medical equipment provider's stock after purchasing an additional 18,840 shares during the quarter. MML Investors Services LLC's holdings in Boston Scientific were worth $9,615,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Parnassus Investments LLC boosted its stake in shares of Boston Scientific by 0.7% during the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after buying an additional 97 shares during the period. Evergreen Capital Management LLC boosted its position in Boston Scientific by 1.7% during the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after purchasing an additional 106 shares during the last quarter. PDS Planning Inc grew its stake in Boston Scientific by 1.5% in the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock valued at $668,000 after purchasing an additional 113 shares in the last quarter. Adero Partners LLC increased its position in Boston Scientific by 3.3% in the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares during the last quarter. Finally, Grove Bank & Trust raised its stake in shares of Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock worth $261,000 after purchasing an additional 122 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on BSX shares. Stifel Nicolaus increased their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Evercore ISI raised their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Raymond James upped their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. Piper Sandler raised their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $114.52.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 6,528 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the sale, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,009 shares of company stock valued at $14,407,381 in the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $0.13 on Tuesday, hitting $102.31. 1,196,739 shares of the company were exchanged, compared to its average volume of 6,343,080. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company's 50 day moving average price is $98.62 and its two-hundred day moving average price is $95.03. Boston Scientific Co. has a one year low of $70.97 and a one year high of $107.17. The firm has a market capitalization of $151.32 billion, a price-to-earnings ratio of 81.80, a PEG ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the company earned $0.56 EPS. Research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.